125 results on '"Simpson, Eric"'
Search Results
2. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
3. Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
4. The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Toward Solutions, and Unique Considerations for Rural and Remote North American Indigenous Populations
5. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
6. Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review
7. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
8. Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial
9. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
10. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
11. The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice
12. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)
13. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
14. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
15. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
16. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
17. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
18. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents
19. Inverse Correlation of TRIM32 and Protein Kinase C ζ in T Helper Type 2–Biased Inflammation
20. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study
21. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients
22. Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis
23. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
24. Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults
25. Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults
26. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
27. Atopic Dermatitis in US Adults: From Population to Health Care Utilization
28. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
29. Health Utility Scores of Atopic Dermatitis in US Adults
30. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”
31. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population
32. Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype
33. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
34. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
35. Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis
36. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
37. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
38. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
39. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
40. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis
41. Topical steroid withdrawal treated with ruxolitinib cream
42. Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévère
43. Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis – Authors' reply
44. 31 - Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others
45. Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions
46. 40900 Tralokinumab modulates the transcriptomic profile of lesional and non-lesional skin in adolescents with moderate-to-severe atopic dermatitis assessed by tape-stripping
47. 43946 Neutralization of IL-13 by tralokinumab improves atopic dermatitis endotypes characterized by S. aureus colonization
48. 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND
49. 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
50. 42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.